Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Maridebart Cafraglutide

A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations

Amgen · Phase 1 · Completed · Enrollment 349

NCT07313761

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Maridebart Cafraglutide SC Presentation 1n/rn/rn/rn/r
Maridebart Cafraglutide SC Presentation 2n/rn/rn/rn/r

Not shown

  • Maridebart Cafraglutide SC Presentation 1: endpoint not reported
  • Maridebart Cafraglutide SC Presentation 2: endpoint not reported